Technical Analysis for ZVRA - Zevra Therapeutics, Inc.

Grade Last Price % Change Price Change
A 8.97 0.00% 0.00
ZVRA closed unchanged on Wednesday, November 20, 2024, on 62 percent of normal volume. The bulls were able to push the stock to a new 52-week high.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
New 52 Week High Strength 0.00%
20 DMA Support Bullish 4.30%
MACD Bearish Signal Line Cross Bearish 4.06%
20 DMA Support Bullish 4.06%
20 DMA Support Bullish -0.66%
New 52 Week Closing High Bullish -0.66%
Pocket Pivot Bullish Swing Setup -0.66%
New 52 Week High Strength -0.66%
Upper Bollinger Band Touch Strength -0.66%
Gapped Down Weakness -0.66%

   Recent Intraday Alerts

Alert Time
Down 2 % about 16 hours ago
Upper Bollinger Band Resistance about 20 hours ago
New 52 Week High about 20 hours ago
Up 3% about 20 hours ago
60 Minute Opening Range Breakout about 21 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Zevra Therapeutics, Inc. Description

Zevra Therapeutics, Inc., a rare disease therapeutics company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. Zevra Therapeutics, Inc. has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Disease Drugs Rare Diseases FDA Psychoactive Drugs Euphoriants Attention Deficit Hyperactivity Disorder Narcolepsy Amphetamine Methylphenidate Hydrocodone Idiopathic Hypersomnia Stimulants

Is ZVRA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 9.27
52 Week Low 4.2
Average Volume 934,821
200-Day Moving Average 6.32
50-Day Moving Average 8.12
20-Day Moving Average 8.56
10-Day Moving Average 8.82
Average True Range 0.52
RSI (14) 59.18
ADX 19.96
+DI 22.09
-DI 13.57
Chandelier Exit (Long, 3 ATRs) 7.70
Chandelier Exit (Short, 3 ATRs) 9.24
Upper Bollinger Bands 9.29
Lower Bollinger Band 7.82
Percent B (%b) 0.78
BandWidth 17.20
MACD Line 0.23
MACD Signal Line 0.23
MACD Histogram -0.0032
Fundamentals Value
Market Cap 351.49 Million
Num Shares 39.2 Million
EPS -1.16
Price-to-Earnings (P/E) Ratio -7.73
Price-to-Sales 14.44
Price-to-Book 3.46
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.81
Resistance 3 (R3) 9.82 9.54 9.67
Resistance 2 (R2) 9.54 9.33 9.54 9.62
Resistance 1 (R1) 9.26 9.20 9.12 9.25 9.58
Pivot Point 8.98 8.98 8.92 8.98 8.98
Support 1 (S1) 8.70 8.77 8.56 8.69 8.36
Support 2 (S2) 8.42 8.64 8.42 8.32
Support 3 (S3) 8.14 8.42 8.27
Support 4 (S4) 8.13